A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

NCT02395133 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

422

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]